The tyrosine kinase inhibitor imatinib that blocks c-KIT and PDGFRA activation is the mainstay treatment for advanced GIST, which has led to improved survival with a median progression-free survival of 18–20 months and a median overall survival of 52–72 months [2,3,4,5]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.